
    
      This Phase II, multicenter, double-blind, randomized, parallel-group, placebo-controlled
      study will evaluate the efficacy and safety of 3 dose levels (10, 20, and 40 mg) of TAK-385
      following oral administration for 12 weeks in women with endometriosis.
    
  